Buchumschlag

Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride-glucose index

Abstract Background and Aims Triglyceride-glucose (TyG) index, is an emerging prognostic biomarker in atherosclerotic cardiovascular disease (ASCVD). Validation of its clinical value and of clinically relevant prognostic cut-off, remains an unmet need to integrate TyG into primary prevention protoco...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mavraganis, Georgios (VerfasserIn) , Georgiopoulos, Georgios (VerfasserIn) , Athanasopoulos, Stavros (VerfasserIn) , Terentes-Printzios, Dimitrios (VerfasserIn) , Zervas, Georgios (VerfasserIn) , Konstantaki, Christina (VerfasserIn) , Koilakou, Maria Eleni (VerfasserIn) , Giannakopoulou, Sofia-Panagiota (VerfasserIn) , Dimopoulou, Maria-Angeliki (VerfasserIn) , Chrysochoou, Christina (VerfasserIn) , Tsioufis, Konstantinos (VerfasserIn) , Pitsavos, Christos (VerfasserIn) , Liberopoulos, Evangelos (VerfasserIn) , Stellos, Konstantinos (VerfasserIn) , Vlachopoulos, Charalambos (VerfasserIn) , Panagiotakos, Demosthenes (VerfasserIn) , Stamatelopoulos, Kimon (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2025
In: Diabetes, obesity and metabolism
Year: 2025, Pages: 1-12
ISSN:1463-1326
DOI:10.1111/dom.70270
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/dom.70270
Verlag, kostenfrei, Volltext: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70270
Volltext
Verfasserangaben:Georgios Mavraganis MD, Georgios Georgiopoulos MD, Stavros Athanasopoulos MD, Dimitrios Terentes-Printzios MD, Georgios Zervas MD, Christina Konstantaki MD, Maria Eleni Koilakou MD, Sofia-Panagiota Giannakopoulou MD, Maria-Angeliki Dimopoulou MD, Christina Chrysochoou MD, Konstantinos Tsioufis MD, Christos Pitsavos MD, Evangelos Liberopoulos MD, Konstantinos Stellos MD, Charalambos Vlachopoulos MD, Demosthenes Panagiotakos PhD, Kimon Stamatelopoulos MD
Beschreibung
Zusammenfassung:Abstract Background and Aims Triglyceride-glucose (TyG) index, is an emerging prognostic biomarker in atherosclerotic cardiovascular disease (ASCVD). Validation of its clinical value and of clinically relevant prognostic cut-off, remains an unmet need to integrate TyG into primary prevention protocols. Methods To assess the clinical applicability of TyG, a composite of cardiovascular mortality, myocardial infarction, coronary revascularization or stroke was used as the primary endpoint in a general population cohort (ATTICA cohort, n?=?1677, derivation cohort). Next, we derived an optimal prognostic TyG cut-off and externally validated it in a primary prevention cohort (n?=?1237). To assess the clinical value of TyG, we analysed 1170 consecutively recruited patients from an ongoing registry aiming to stratify ASCVD risk (Athens Cardiometabolic Cohort) and assessed indices of subclinical arterial injury and progression of atherosclerosis. The TyG index was calculated by the formula: ln[fasting triglycerides (mg/dL)???fasting glucose (mg/dL)/2]. Results TyG index was independently associated with increased CVD events in the derivation cohort (HR?=?1.33, p?=?0.020). The incremental value of a derived optimal cut-off of 8.46 over SCORE2 was confirmed in both derivation and validation cohorts [net reclassification index (NRI)?=?0.668 and 0.469 respectively, Delta Harrell's C index?=?0.054 and 0.044 respectively, p?
Beschreibung:Erstmals veröffentlicht: 3. November 2025
Gesehen am 24.11.2025
Beschreibung:Online Resource
ISSN:1463-1326
DOI:10.1111/dom.70270

Ähnliche Einträge